Effective control of recalcitrant pruritus by bevacizumab: A Possible Role for Vascular Endothelial Growth Factor in Chronic Itch?

Acta Dermato-Venereologica

Volumn 93, Issue 2, 2013, Pages 175-179

  Krause, Karoline ^a   Krul, Clemens ^a   Ke, BirgitSSler ^a   Lange Asschenfeldt, Bernhard ^a   Maurer, Marcus ^a   Metz, Martin ^a  

^a CHARITÉ UNIVERSITÄTSMEDIZIN BERLIN   (Germany)

Author keywords

Itch; Prurigo; Pruritus; VEGF

Indexed keywords

BEVACIZUMAB; VASCULOTROPIN;

AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DISEASE ACTIVITY; FEMALE; HUMAN; MALE; PAPULAR URTICARIA; PATHOPHYSIOLOGY; PHYSICIAN; PRIORITY JOURNAL; PROSPECTIVE STUDY; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION;

AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTIPRURITICS; BIOLOGICAL MARKERS; BIOPSY; CASE-CONTROL STUDIES; FEMALE; HUMANS; MALE; MIDDLE AGED; PROSPECTIVE STUDIES; PRURIGO; PRURITUS; SEVERITY OF ILLNESS INDEX; SKIN; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 84875074226     PISSN: 00015555     EISSN: 16512057     Source Type: Journal    
DOI: 10.2340/00015555-1445     Document Type: Article

References (18)

1. Ständer S, Weisshaar E, Mettang T, Szepietowski JC, Carstens E, Ikoma A, et al. Clinical classification of itch: a position paper of the International Forum for the Study of Itch. Acta Derm Venereol 2007; 87: 291-294.
2. Iking A, Grundmann S, Chatzigeorgakidis E, Phan NQ, Klein D, Stander S. Prurigo as a symptom of atopic and non-atopic diseases: aetiological survey in a consecutive cohort of 108 patients. J Eur Acad Dermatol Venereol (in press).
3. Fukushi S, Yamasaki K, Aiba S. Nuclear localization of activated STAT6 and STAT3 in epidermis of prurigo nodularis. Br J Dermatol 2011; 165: 990-996.
4. Feldmeyer L, Werner S, Kamarashev J, French LE, Hofbauer GF. Atopic prurigo nodularis responds to intravenous immunoglobulins. Br J Dermatol 2012; 166: 461-462.
5. Hammes S, Hermann J, Roos S, Ockenfels HM. UVB 308-nm excimer light and bath PUVA: combination therapy is very effective in the treatment of prurigo nodularis. J Eur Acad Dermatol Venereol 2011; 25: 799-803.
6. Metz M, Ständer S. Chronic pruritus-pathogenesis, clinical aspects and treatment. J Eur Acad Dermatol Venereol 2010; 24: 1249-1260.
7. Ständer S, Siepmann D, Herrgott I, Sunderkötter C, Luger TA. Targeting the neurokinin receptor 1 with aprepitant: a novel antipruritic strategy. PLoS One 2010; 5: e10968.
8. Takahashi S. Vascular endothelial growth factor (VEGF), VEGF receptors and their inhibitors for antiangiogenic tumor therapy. Biol Pharmaceut Bull 2011; 34: 1785-1788.
9. Ferrara N, Hillan KJ, Gerber HP, Novotny W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nature Rev Drug Discovery 2004; 3: 391-400.
10. Ranpura V, Hapani S, Wu S. Treatment-related mortality with bevacizumab in cancer patients: a meta-analysis. JAMA 2011; 305: 487-494.
11. von Minckwitz G, Eidtmann H, Loibl S, Blohmer JU, Costa SD, Fasching PA, et al. ntegrating bevacizumab, everolimus, and lapatinib into current neoadjuvant chemotherapy regimen for primary breast cancer. Safety results of the GeparQuinto trial. Ann Oncol 2011; 22: 301-306.
12. Horiuchi T, Weller PF. Expression of vascular endothelial growth factor by human eosinophils: upregulation by granulocyte macrophage colony-stimulating factor and interleukin-5. Am J Respir Cell Mol Biol 1997; 17: 70-77.
13. Kakurai M, Demitsu T, Umemoto N, Kobayashi Y, Inoue-Narita T, Fujita N, et al. Vasoactive intestinal peptide and inflammatory cytokines enhance vascular endothelial growth factor production from epidermal keratinocytes. Br J Dermatol 2009; 161: 1232-1238.
14. Smith JR, Lanier VB, Braziel RM, Falkenhagen KM, White C, Rosenbaum JT. Expression of vascular endothelial growth factor and its receptors in rosacea. Br J Ophthalmol 2007; 91: 226-229.
15. Wang H, Byfield G, Jiang Y, Smith GW, McCloskey M, Hartnett ME. VEGF-mediated STAT3 activation inhibits retinal vascularization by down-regulating local erythropoietin expression. Am J Pathol 2012; 180: 1243-1253.
16. Ptaszynska MM, Pendrak ML, Stracke ML, Roberts DD. Autotaxin signaling via lysophosphatidic acid receptors contributes to vascular endothelial growth factor-induced endothelial cell migration. Mol Cancer Res 2010; 8: 309-321.
17. Kremer AE, Dijk RV, Leckie P, Schaap FG, Kuiper EM, Mettang T, et al. Serum autotaxin is increased in pruritus of cholestasis, but not of other origin and responds to herapeutic interventions. Hepatology 2012; 56: 1391-1400.
18. Vaa BE, Wolanskyj AP, Roeker L, Pardanani A, Lasho TL, Finke CM, et al. Pruritus in primary myelofibrosis: clinical and laboratory correlates. Am J Hematol 2012; 87: 136-138.